CHICAGO, October 20, 2016 – The Muscular Dystrophy Association (MDA) and RYR-1 Foundation today announced a partnership aimed at advancing research and clinical care, raising awareness, and improving education of patients, medical professionals and the public about RYR1-related myopathies.
The partnership represents a key step in MDA’s commitment to form collaborative relationships with other organizations working on the same diseases MDA covers.
Alliance Focuses On Supporting Promising, Young ALS Investigators
CHICAGO, September 28, 2016 – The Muscular Dystrophy Association (MDA) and Target ALS Foundation today announced a partnership aimed at advancing ALS research and therapy development. Through the alliance, the two organizations will work together to support talented, young scientists who choose to pursue a career devoted to ALS research.
Approval expected to hasten development of treatments for DMD and related diseases
CHICAGO, Sept. 19, 2016— The Muscular Dystrophy Association today celebrated news of the U.S. Food and Drug Administration’s decision to grant accelerated approval for eteplirsen, the first disease-modifying drug to treat the most common childhood form of muscular dystrophy.